IDH1 and acute myeloid leukemia: Due to their excellent performance in clinical trial, the IDH inhibitors ivosidenib and enasidenib are approved by Food and Drug Administration (FDA) to treat adults with relapsed and refractory AML with IDH1/2 mutation.